EAACI过敏原免疫治疗指南:膜翅目昆虫毒液过敏
膜翅目昆虫毒液过敏是蜜蜂、胡蜂或蚂蚁蜇伤后可能危及生命的过敏反应,成人全身性过敏蜇伤反应报告率高达7.5%,儿童高达3.4%。患者应根据既往蜇伤反应严重程度携带含肾上腺素自动注射器、H1抗组胺药和皮质类固醇的急救包。唯一能预防进一步全身性蜇伤反应的治疗是毒液免疫治疗。该指南由欧洲过敏与临床免疫学会(EAACI)毒液免疫治疗工作组制定,基于正式系统评价和荟萃分析,采用AGREE II方法,为毒液免疫治疗的实施提供循证推荐和实用建议。
要点
- 毒液免疫治疗适用于毒液过敏儿童和成人,以预防进一步中重度全身性蜇伤反应。
- 仅有全身皮肤反应的成人也推荐毒液免疫治疗,因与携带肾上腺素自动注射器相比可显著改善生活质量。
- 患者应根据既往蜇伤反应严重程度携带急救包,内含肾上腺素自动注射器、H1抗组胺药和皮质类固醇。
- 成人全身性过敏蜇伤反应报告率高达7.5%,儿童高达3.4%,反应可从仅限皮肤的轻度到危及生命的重度过敏反应。
- 毒液免疫治疗是唯一能预防进一步全身性蜇伤反应的治疗。
适用人群与场景
- 毒液过敏儿童和成人,用于预防进一步中重度全身性蜇伤反应。
- 仅有全身皮肤反应的成人也适用毒液免疫治疗。
处置流程与药物剂量
- 患者应根据既往蜇伤反应严重程度携带急救包,内含肾上腺素自动注射器、H1抗组胺药和皮质类固醇。
- 毒液免疫治疗用于毒液过敏儿童和成人以预防进一步中重度全身性蜇伤反应。
- 仅有全身皮肤反应的成人也推荐毒液免疫治疗,因与携带肾上腺素自动注射器相比可显著改善生活质量。
研究设计与关键结果
- 指南由欧洲过敏与临床免疫学会(EAACI)毒液免疫治疗工作组制定,基于正式系统评价和荟萃分析,采用AGREE II方法,过程包括多种利益相关方代表。
- 指南旨在提供毒液免疫治疗的循证推荐,关键部分涵盖启动毒液免疫治疗前的一般考虑、循证临床推荐、不良事件和全身性蜇伤反应复发的危险因素以及证据缺口总结。
证据类型、等级与局限
- 证据类型:指南,基于正式系统评价和荟萃分析,采用AGREE II方法制定。
- 局限:原文未报告局限性
对床旁实践的改变
- 原文推荐毒液免疫治疗用于毒液过敏儿童和成人以预防进一步中重度全身性蜇伤反应,也推荐用于仅有全身皮肤反应的成人。
- 原文建议患者根据既往蜇伤反应严重程度携带含肾上腺素自动注射器、H1抗组胺药和皮质类固醇的急救包。
指南或共识出处
- EAACI指南:过敏原免疫治疗——膜翅目昆虫毒液过敏,欧洲过敏与临床免疫学会(EAACI),年份原文未写明
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
Hymenoptera venom allergy is a potentially life-threatening allergic reaction following a honeybee, vespid, or ant sting. Systemic-allergic sting reactions have been reported in up to 7.5% of adults and up to 3.4% of children. They can be mild and restricted to the skin or moderate to severe with a risk of life-threatening anaphylaxis. Patients should carry an emergency kit containing an adrenaline autoinjector, H1 -antihistamines, and corticosteroids depending on the severity of their previous sting reaction(s). The only treatment to prevent further systemic sting reactions is venom immunotherapy. This guideline has been prepared by the European Academy of Allergy and Clinical Immunology's (EAACI) Taskforce on Venom Immunotherapy as part of the EAACI Guidelines on Allergen Immunotherapy initiative. The guideline aims to provide evidence-based recommendations for the use of venom immunotherapy, has been informed by a formal systematic review and meta-analysis and produced using the Appraisal of Guidelines for Research and Evaluation (AGREE II) approach. The process included representation from a range of stakeholders. Venom immunotherapy is indicated in venom-allergic children and adults to prevent further moderate-to-severe systemic sting reactions. Venom immunotherapy is also recommended in adults with only generalized skin reactions as it results in significant improvements in quality of life compared to carrying an adrenaline autoinjector. This guideline aims to give practical advice on performing venom immunotherapy. Key sections cover general considerations before initiating venom immunotherapy, evidence-based clinical recommendations, risk factors for adverse events and for relapse of systemic sting reaction, and a summary of gaps in the evidence.
参考来源
- Sturm GJ, Varga EM, Roberts G, et al. EAACI guidelines on allergen immunotherapy: Hymenoptera venom allergy. Allergy. 2017. PMID: 28748641. doi:10.1111/all.13262
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。